78
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Pretreatment with intraluminal rapamycin nanoparticle perfusion inhibits neointimal hyperplasia in a rabbit vein graft model

, , , , &
Pages 853-860 | Published online: 11 Oct 2010

References

  • ShuhaiberJHEvansANMassadMGGehaASMechanisms and future directions for prevention of vein graft failure in coronary bypass surgeryEur J CardioThorac Surg200222338739612204729
  • ShahPJGordonIFullerJFactors affecting saphenous vein graft patency: Clinical and angiography study in 1402 symptomatic patients operated on between 1977 and 1999J Thorac Cardiovasc Surg200312661972197714688715
  • RousouLJTaylorKBLuXGSaphenous vein conduits harvested by endoscopic technique exhibit structural and functional damageAnn Thorac Surg2009871627019101270
  • ZillaPHumanPWolfMConstrictive external nitinol meshes inhibit vein graft intimal hyperplasia in nonhuman primatesJ Thorac Cardiovasc Surg2008136371772518805277
  • SchachnerTPharmacologic inhibition of vein graft neointimal hyperplasiaJ Thorac Cardiovasc Surg200613151065107216678591
  • MarksARSirolimus for the prevention of in-stent restenosis in a coronary arteryN Engl J Med2003349141307130914523135
  • SchachnerTOberhuberAZouYRapamycin treatment is associated with an increased apoptosis rate in experimental vein graftsEur J Cardiothorac Surg200527230230615691686
  • MehilliJByrneRAWieczorekARandomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosisEur Heart J200829161975198218550554
  • KotaniJAwataMNantoSIncomplete neointimal coverage of sirolimus-eluting stentsJ Am Coll Cardiol200647102108211116697331
  • WalpothBHAdverse effects of local or systemic application of rapamycin for the prevention of neointimal hyperplasiaAnn Thorac Surg20057962201220215919358
  • RajathuraiTRizviSILinHAngeliniGDNewbyACMurphyGJPeriadventitial rapamycin-eluting microbeads promote vein graft disease in long-term pig vein-into-artery interposition grafts201032157165
  • SteffelJEberliFRLüscherTFTannerFCDrug-eluting stents – what should be improved?Ann Med200840424225218428018
  • VirmaniRGuagliumiGFarbALocalized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent – should we be cautious?Circulation2004109670170514744976
  • DongYFengSSPoly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugsBiomaterials200526306068607615894372
  • KimDHMartinDCSustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug deliveryBiomaterials200627153031303716443270
  • VandervoortJLudwigABiocompatible stabilizers in the preparation of PLGA nanoparticles: A factorial design studyInt J Pharm200223812779211996805
  • GrabovacVGuggiDBernkop-SchnürchAComparison of the mucoadhesive properties of various polymersAdv Drug Deliv Rev200557111713172316183163
  • ZhangLFXiaoFLiJWangJShiZHLiCYLocal applied slow-releasing rapamycin inhibits neointima hyperplasia in vein graftZhonghua Yi Xue Za Zhi200686241706170916854327
  • SchachnerTZouYOberhuberALocal application of rapamycin inhibits neointimal hyperplasia in experimental vein graftsAnn Thorac Surg20047751580150515111146
  • KawatsuSOdaKSaikiYTabataYTabayashiKExternal application of rapamycin-eluting film at anastomotic sites inhibits neointimal hyperplasia in a canine modelAnn Thorac Surg200784256056717643635
  • GuzmanLALabhasetwarVSongCLocal intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplastyCirculation1996946144114488823004
  • MiaoLFYangJHuangCLRapamycin-loaded poly (lactic-co-glycolic) acid nanoparticles for intrarterial local drug delivery: Preparation, characterization, and in vitro/in vivo releaseZhongguo Yi Xue Ke Xue Yuan Xue Bao200830449149718795627
  • ZouWCaoGXiYZhangNNew approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticlesDrug Deliv2009161152319555304
  • BauriedelGJabsAKraemerSNickenigGSkowaschDNeointimal expression of rapamycin receptor FK506-binding protein FKBP12: Postinjury animal and human in-stent restenosis tissue characteristicsJ Vasc Res200845217317817962721
  • HashemolhosseiniSNagamineYMorleySJDesrivièresSMercepLFerrariSRapamycin inhibition of the G1 to S transition is mediated by effects on Cyclin Dl mRNA and protein stabilityJ Biol Chem19982732314424144299603954
  • SemsrothSStiglerRGBerneckerOYEverolimus attenuates neointimal hyperplasia in cultured human saphenous vein graftsEur J Cardiothorac Surg200935351552019167904
  • HuXHZhangQYangJThe expression of mammalian target of rapamycin and its substrates in autogenous vein graft in ratsZhonghua Wai Ke Za Zhi200644151053105717074246
  • WestedtUKalinowskiMWittmarMPoly (vinylalcohol)- graft-poly (lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatmentJ Control Release2007191415117346845
  • YangJZengYLiYIntravascular site-specific delivery of a therapeutic antisense for the inhibition of restenosisEur J Pharm Sci200835542743418848882
  • FengSSZengWTeng LimYVitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatmentNanomedicine (Lond)20072333334417716178
  • CagiannosCAbul-KhoudoudORDeRijkWRapamycin-coated expanded polytetrafluoroethylene bypass grafts exhibit decreased anastomotic neointimal hyperplasia in a porcine modelJ Vasc Surg200542598098816275457
  • CarterAJAggarwalMKopiaGALong-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary modelCardiovasc Res200463461762415306217